Latest news with #ProMedicus
Sky News AU
01-08-2025
- Business
- Sky News AU
ASX plunges as Trump tariffs trigger healthcare, tech stock sell-off
Technology, healthcare and the big four banks led the market sell-off on Friday as US President Donald Trump made two announcements that smashed the Asian markets. The benchmark ASX 200 slumped 80.80 points or 0.92 per cent to 8662, while the broader All Ordinaries fell 81.90 points or 0.91 per cent to 8917.10. Australia's dollar gained against the greenback and is now buying 64.25 US cents. On an overall sea of red, 10 of the 11 sectors finished in the red. The utilities sector was the only sector to trade higher. Healthcare shares were among the major market falls after Mr Trump wrote letters to the 17 largest US drug companies demanding they lower prices for local consumers, making up the difference in other foreign countries. CSL slumped 2.53 per cent to $264.05, Pro Medicus dropped 2.45 per cent to $313.99 and Sigma Healthcare finished in the red down 1.04 per cent to $2.86. Technology stocks also led the falls. WiseTech Global dropped 2.55 per cent to $116.34, Xero fell 3.45 per cent to $174.75 and Technology One slumped 2.17 per cent to $40.19. Three of the big four banks also slumped. CBA led the losses down 1.60 per cent to $175.06, NAB dropped 1.21 per cent to $38.44 and Westpac slipped 1.09 per cent to $33.45. ANZ bucked the trend gaining 0.49 per cent to $30.87. The second announcement that rattled Asian markets was an announcement from the President around tariffs. While Australia will only face the 'base rate' of 10 per cent, many of the US trading partners will face higher levies, which is feared to slow down global growth. According to Commonwealth Bank's senior economist and senior currency strategist Kristina Clifton, US tariffs are now at their highest level since the 1930s. 'We expect the large increase in the US's global effective tariff rate will raise US business and consumer prices, weighing on purchasing power and demand,' Ms Clifton wrote in an economic note. But the impact on Australia is tipped to be relatively subdued. 'We estimate Australian GDP will be just 0.3 per cent lower over a few years because of the tariffs,' Ms Clifton said. Only about five per cent of Australia's exports are to the US and Australia's tariff rate is a relatively low 10 per cent. In company news, Star Entertainment will be forced to pay about $41m back to Hong Kong-based business partners, Chow Tai Fook Enterprises and Far East Consortium after a deal to buy the newly opened Queen's Wharf hotel and casino complex fell through. In a statement to the ASX on Friday, Star Entertainment confirmed it was 'unable to reach an agreement,' and will now be liable for almost $1bn in debt for the precinct. Shares plunged 16.36 per cent to $0.09. Five ways Trump's tariffs will impact youHouse prices defy RBA rate hold Shares in diversified investment house Soul Patts slipped 0.64 per cent to $40.32 after announcing preliminary, unaudited net asset values to come in between $12.18 to $12.68bn for the year ending July 31. Resmed shares flirted with a record high after the medical sleep device maker announced profits that beat market expectations. Shares jumped 1.01 per cent to $42.88. Originally published as Banks, healthcare drop on two Trump moves
Perth Now
01-08-2025
- Business
- Perth Now
ASX slumps on latest Trump tariff rates
Technology, healthcare and the big four banks led the market sell-off on Friday as US President Donald Trump made two announcements that smashed the Asian markets. The benchmark ASX 200 slumped 80.80 points or 0.92 per cent to 8662, while the broader All Ordinaries fell 81.90 points or 0.91 per cent to 8917.10. Australia's dollar gained against the greenback and is now buying 64.25 US cents. On an overall sea of red, 10 of the 11 sectors finished in the red. The utilities sector was the only sector to trade higher. Healthcare shares were among the major market falls after Mr Trump wrote letters to the 17 largest US drug companies demanding they lower prices for local consumers, making up the difference in other foreign countries. CSL slumped 2.59 per cent to $262.88, Pro Medicus dropped 2.40 per cent to $314.17 and Sigma Healthcare finished in the red down 1.21 per cent to $2.855. Technology stocks also led the falls. WiseTech Global dropped 2.35 per cent to $116.57, Xero fell 3.20 per cent to $175.19 and Technology One slumped 2.02 per cent to $40.25. Three of the big four banks also slumped. CBA led the losses down 1.64 per cent to $175, NAB dropped 1.29 per cent to $38.41 and Westpac slipped 0.95 per cent to $33.50. ANZ bucked the trend gaining 0.72 per cent to $30.94. The second announcement that rattled Asian markets was an announcement from the President around tariffs. While Australia will only face the 'base rate' of 10 per cent, many of the US trading partners will face higher levies, which is feared to slow down global growth. According to Commonwealth Bank's senior economist and senior currency strategist Kristina Clifton, US tariffs are now at their highest level since the 1930s. 'We expect the large increase in the US's global effective tariff rate will raise US business and consumer prices, weighing on purchasing power and demand,' Ms Clifton wrote in an economic note. The economic fallout for Australia from Trump's tariffs is expected to be minimal. Gaye Gerard / NewsWire Credit: News Corp Australia But the impact on Australia is tipped to be relatively subdued. 'We estimate Australian GDP will be just 0.3 per cent lower over a few years because of the tariffs,' Ms Clifton said. Only about five per cent of Australia's exports are to the US and Australia's tariff rate is a relatively low 10 per cent. In company news, Star Entertainment will be forced to pay about $41m back to Hong Kong-based business partners, Chow Tai Fook Enterprises and Far East Consortium after a deal to buy the newly opened Queen's Wharf hotel and casino complex fell through. In a statement to the ASX on Friday, Star Entertainment confirmed it was 'unable to reach an agreement,' and will now be liable for almost $1bn in debt for the precinct. Shares plunged 16.36 per cent to $0.09. Shares in diversified investment house Soul Patts slipped 0.64 per cent to $40.32 after announcing preliminary, unaudited net asset values to come in between $12.18 to $12.68bn for the year ending July 31. Resmed shares flirted with a record high after the medical sleep device maker announced profits that beat market expectations. Shares jumped 1.01 per cent to $42.88.
Yahoo
20-07-2025
- Business
- Yahoo
High Growth Tech Stocks in Australia Featuring Life360 and Two Others
The Australian market is experiencing a bullish trend, with the ASX reaching new all-time highs, driven by positive sentiment from Wall Street and expectations of potential rate cuts by the Reserve Bank of Australia in response to rising unemployment. In this environment, high-growth tech stocks like Life360 are garnering attention for their potential to capitalize on favorable economic conditions and investor optimism. Top 10 High Growth Tech Companies In Australia Name Revenue Growth Earnings Growth Growth Rating Pro Medicus 20.17% 22.26% ★★★★★★ Gratifii 42.14% 113.99% ★★★★★★ Echo IQ 49.20% 51.35% ★★★★★★ WiseTech Global 20.46% 23.23% ★★★★★★ BlinkLab 51.57% 52.67% ★★★★★★ Wrkr 55.92% 116.30% ★★★★★★ Pointerra 50.42% 159.12% ★★★★★☆ Immutep 70.84% 42.55% ★★★★★☆ Adveritas 52.34% 88.83% ★★★★★★ SiteMinder 18.77% 55.55% ★★★★★☆ Click here to see the full list of 45 stocks from our ASX High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Life360 Simply Wall St Growth Rating: ★★★★★☆ Overview: Life360, Inc. operates a technology platform that provides location services for people, pets, and things across various regions globally, with a market capitalization of A$8.63 billion. Operations: The company generates revenue primarily from its software and programming segment, amounting to $396.88 million. Its technology platform is utilized across North America, Europe, the Middle East, Africa, and other international markets. Despite recent volatility, including its drop from several Russell indexes, Life360 has shown resilience and strategic foresight in the high-growth tech sector. The company's revenue is expected to grow by 16.1% annually, outpacing the Australian market's 5.5%, while earnings are forecasted to surge by an impressive 40.6% per year. This growth trajectory is supported by innovative advertising solutions like Place Ads and Uplift by Life360, which leverage real-world behavior to deliver targeted ads, evidenced by their partnership with Uber that generated over 100,000 rides from airport travelers alone. With $308.9 million raised from a convertible notes offering aimed at funding acquisitions and strategic investments, Life360 is poised to expand its technological footprint and enhance shareholder value through smart capital allocation. Take a closer look at Life360's potential here in our health report. Gain insights into Life360's historical performance by reviewing our past performance report. Codan Simply Wall St Growth Rating: ★★★★☆☆ Overview: Codan Limited specializes in creating technology solutions for various clients, including United Nations organizations, security and military groups, government departments, individuals, and small-scale miners, with a market capitalization of A$3.67 billion. Operations: Codan Limited generates revenue primarily from its Communications and Metal Detection segments, with A$360.27 million and A$224.90 million respectively. The company focuses on providing technology solutions to a diverse range of clients, including governmental and military entities, as well as individuals in niche markets. With a robust 19.4% increase in earnings over the past year, Codan has outperformed the Electronic industry's growth of 8.9%, showcasing its competitive edge in a challenging market. The company's revenue is expected to rise by 10.8% annually, surpassing the broader Australian market's growth rate of 5.6%. This financial vitality is underpinned by Codan's commitment to innovation, as evidenced by its R&D expenses that strategically fuel advancements and efficiency in its operations. Looking ahead, while earnings are projected to grow at a steady rate of 15.76% per year, it's clear that Codan is not just keeping pace but setting the pace in its sector through strategic investments and a keen focus on sustainable growth. Click to explore a detailed breakdown of our findings in Codan's health report. Explore historical data to track Codan's performance over time in our Past section. Xero Simply Wall St Growth Rating: ★★★★☆☆ Overview: Xero Limited offers online business solutions tailored for small businesses and their advisors across Australia, New Zealand, the United Kingdom, North America, and other international markets, with a market capitalization of approximately A$29.80 billion. Operations: The company generates revenue primarily from providing online solutions for small businesses and their advisors, amounting to NZ$2.10 billion. Its operations span Australia, New Zealand, the United Kingdom, North America, and other international markets. Xero's recent performance and strategic initiatives position it as a dynamic entity in the tech landscape, particularly within the software industry where it has outpaced its peers with a 30.4% earnings growth over the past year. This growth is significantly higher than the industry average of 5.6%. The company's commitment to innovation is evident from its R&D spending, which has been crucial in maintaining this momentum; however, specific figures were not disclosed. Additionally, Xero recently enhanced its platform through partnerships and integrations, such as with BILL for streamlined bill payments in the U.S., reflecting a proactive approach to addressing client needs and improving cash flow management for small businesses. These moves not only enhance Xero's service offering but also solidify its standing in competitive markets by adapting to evolving business environments. Click here to discover the nuances of Xero with our detailed analytical health report. Understand Xero's track record by examining our Past report. Next Steps Embark on your investment journey to our 45 ASX High Growth Tech and AI Stocks selection here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Ready For A Different Approach? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:360 ASX:CDA and ASX:XRO. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
20-07-2025
- Business
- Yahoo
The recent 3.4% gain must have brightened CEO Sam Hupert's week, Pro Medicus Limited's (ASX:PME) most bullish insider
Key Insights Pro Medicus' significant insider ownership suggests inherent interests in company's expansion 51% of the business is held by the top 4 shareholders 14% of Pro Medicus is held by Institutions We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Pro Medicus Limited (ASX:PME) can tell us which group is most powerful. The group holding the most number of shares in the company, around 49% to be precise, is individual insiders. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Clearly, insiders benefitted the most after the company's market cap rose by AU$1.1b last week. Let's take a closer look to see what the different types of shareholders can tell us about Pro Medicus. See our latest analysis for Pro Medicus What Does The Institutional Ownership Tell Us About Pro Medicus? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Pro Medicus does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Pro Medicus, (below). Of course, keep in mind that there are other factors to consider, too. Hedge funds don't have many shares in Pro Medicus. The company's CEO Sam Hupert is the largest shareholder with 23% of shares outstanding. With 23% and 2.9% of the shares outstanding respectively, Anthony Hall and The Vanguard Group, Inc. are the second and third largest shareholders. Interestingly, the second-largest shareholder, Anthony Hall is also Top Key Executive, again, pointing towards strong insider ownership amongst the company's top shareholders. To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Insider Ownership Of Pro Medicus While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. It seems insiders own a significant proportion of Pro Medicus Limited. It has a market capitalization of just AU$34b, and insiders have AU$17b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 37% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Pro Medicus better, we need to consider many other factors. I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19-07-2025
- Business
- Yahoo
The recent 3.4% gain must have brightened CEO Sam Hupert's week, Pro Medicus Limited's (ASX:PME) most bullish insider
Key Insights Pro Medicus' significant insider ownership suggests inherent interests in company's expansion 51% of the business is held by the top 4 shareholders 14% of Pro Medicus is held by Institutions We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Pro Medicus Limited (ASX:PME) can tell us which group is most powerful. The group holding the most number of shares in the company, around 49% to be precise, is individual insiders. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Clearly, insiders benefitted the most after the company's market cap rose by AU$1.1b last week. Let's take a closer look to see what the different types of shareholders can tell us about Pro Medicus. See our latest analysis for Pro Medicus What Does The Institutional Ownership Tell Us About Pro Medicus? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Pro Medicus does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Pro Medicus, (below). Of course, keep in mind that there are other factors to consider, too. Hedge funds don't have many shares in Pro Medicus. The company's CEO Sam Hupert is the largest shareholder with 23% of shares outstanding. With 23% and 2.9% of the shares outstanding respectively, Anthony Hall and The Vanguard Group, Inc. are the second and third largest shareholders. Interestingly, the second-largest shareholder, Anthony Hall is also Top Key Executive, again, pointing towards strong insider ownership amongst the company's top shareholders. To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Insider Ownership Of Pro Medicus While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. It seems insiders own a significant proportion of Pro Medicus Limited. It has a market capitalization of just AU$34b, and insiders have AU$17b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 37% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Pro Medicus better, we need to consider many other factors. I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
